HEADER TRANSFERASE 04-JAN-08 3BV2 TITLE MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR TITLE 2 COMPOUND 30 COMPND MOL_ID: 1; COMPND 2 MOLECULE: MITOGEN-ACTIVATED PROTEIN KINASE 14; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: MITOGEN-ACTIVATED PROTEIN KINASE P38 ALPHA, MAP COMPND 5 KINASE P38 ALPHA, CYTOKINE SUPPRESSIVE ANTI-INFLAMMATORY COMPND 6 DRUG-BINDING PROTEIN, CSAID-BINDING PROTEIN, CSBP, MAX- COMPND 7 INTERACTING PROTEIN 2, MAP KINASE MXI2, SAPK2A; COMPND 8 EC: 2.7.11.24; COMPND 9 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_CELL_LINE: BL21 DE3; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID KEYWDS SERINE/THREONINE-PROTEIN KINASE, KINASE, TRANSFERASE, P38 KEYWDS 2 MAP KINASE, ALTERNATIVE SPLICING, ATP-BINDING, CYTOPLASM, KEYWDS 3 NUCLEOTIDE-BINDING, NUCLEUS, PHOSPHOPROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR J.S.SACK REVDAT 3 24-FEB-09 3BV2 1 VERSN REVDAT 2 20-MAY-08 3BV2 1 JRNL REVDAT 1 08-APR-08 3BV2 0 JRNL AUTH S.T.WROBLESKI,S.LIN,J.HYNES,H.WU,S.PITT,D.R.SHEN, JRNL AUTH 2 R.ZHANG,K.M.GILLOOLY,D.J.SHUSTER,K.W.MCINTYRE, JRNL AUTH 3 A.M.DOWEYKO,K.F.KISH,J.A.TREDUP,G.J.DUKE,J.S.SACK, JRNL AUTH 4 M.MCKINNON,J.DODD,J.C.BARRISH,G.L.SCHIEVEN, JRNL AUTH 5 K.LEFTHERIS JRNL TITL SYNTHESIS AND SAR OF NEW JRNL TITL 2 PYRROLO[2,1-F][1,2,4]TRIAZINES AS POTENT P38 ALPHA JRNL TITL 3 MAP KINASE INHIBITORS. JRNL REF BIOORG.MED.CHEM.LETT. V. 18 2739 2008 JRNL REFN ISSN 0960-894X JRNL PMID 18364256 JRNL DOI 10.1016/J.BMCL.2008.02.067 REMARK 1 REMARK 2 REMARK 2 RESOLUTION. 2.40 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER-TNT 2.1.1 REMARK 3 AUTHORS : BLANC,ROVERSI,VONRHEIN,BRICOGNE,TRONRUD, REMARK 3 : TEN EYCK,MATTHEWS REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.40 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 37.09 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 93.3 REMARK 3 NUMBER OF REFLECTIONS : 14230 REMARK 3 REMARK 3 USING DATA ABOVE SIGMA CUTOFF. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.209 REMARK 3 R VALUE (WORKING SET) : 0.206 REMARK 3 FREE R VALUE : 0.263 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.990 REMARK 3 FREE R VALUE TEST SET COUNT : 710 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 9 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.40 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.54 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 93.27 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 1631 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2604 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1534 REMARK 3 BIN R VALUE (WORKING SET) : 0.2557 REMARK 3 BIN FREE R VALUE : 0.3371 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.95 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 97 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2721 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 44 REMARK 3 SOLVENT ATOMS : 97 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 52.73 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 47.14 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 5.38560 REMARK 3 B22 (A**2) : 5.52363 REMARK 3 B33 (A**2) : -10.90923 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : NULL REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES RMS WEIGHT COUNT REMARK 3 BOND LENGTHS (A) : 0.006 ; 2.000 ; 2832 REMARK 3 BOND ANGLES (DEGREES) : 0.920 ; 2.000 ; 3829 REMARK 3 TORSION ANGLES (DEGREES) : 26.566 ; 0.000 ; 559 REMARK 3 PSEUDOROTATION ANGLES (DEGREES) : NULL ; NULL ; NULL REMARK 3 TRIGONAL CARBON PLANES (A) : 0.007 ; 2.000 ; 82 REMARK 3 GENERAL PLANES (A) : 0.012 ; 5.000 ; 400 REMARK 3 ISOTROPIC THERMAL FACTORS (A**2) : 1.335 ; 20.000; 2832 REMARK 3 NON-BONDED CONTACTS (A) : 0.037 ; 5.000 ; 73 REMARK 3 REMARK 3 INCORRECT CHIRAL-CENTERS (COUNT) : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 3BV2 COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 18-JAN-08. REMARK 100 THE RCSB ID CODE IS RCSB045991. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 26-AUG-01 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-BM REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 14286 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.400 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 93.4 REMARK 200 DATA REDUNDANCY : 6.700 REMARK 200 R MERGE (I) : 0.06700 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 14.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.40 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.49 REMARK 200 COMPLETENESS FOR SHELL (%) : 62.5 REMARK 200 DATA REDUNDANCY IN SHELL : 2.60 REMARK 200 R MERGE FOR SHELL (I) : 0.24400 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.400 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.48 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.30 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1-6% (W/V) PEG-4K, 50 MM MES, 5 MM REMARK 280 MAGNESIUM SULFATE, PH 6.0 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 32.43950 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 38.92400 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 37.08750 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 38.92400 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 32.43950 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 37.08750 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A -5 REMARK 465 ALA A -4 REMARK 465 HIS A -3 REMARK 465 HIS A -2 REMARK 465 HIS A -1 REMARK 465 HIS A 0 REMARK 465 HIS A 1 REMARK 465 SER A 2 REMARK 465 GLN A 3 REMARK 465 GLU A 4 REMARK 465 HIS A 174 REMARK 465 THR A 175 REMARK 465 ASP A 176 REMARK 465 ASP A 177 REMARK 465 GLU A 178 REMARK 465 MET A 179 REMARK 465 THR A 180 REMARK 465 GLY A 181 REMARK 465 TYR A 182 REMARK 465 VAL A 183 REMARK 465 PRO A 352 REMARK 465 LEU A 353 REMARK 465 ASP A 354 REMARK 465 GLN A 355 REMARK 465 GLU A 356 REMARK 465 GLU A 357 REMARK 465 MET A 358 REMARK 465 GLU A 359 REMARK 465 SER A 360 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO A 6 -161.16 -118.74 REMARK 500 GLN A 11 148.92 170.79 REMARK 500 ASN A 14 -51.10 69.15 REMARK 500 LYS A 15 13.53 157.42 REMARK 500 SER A 32 -156.56 -122.08 REMARK 500 ALA A 34 -121.28 89.48 REMARK 500 SER A 37 119.44 68.89 REMARK 500 ARG A 57 58.72 39.06 REMARK 500 PHE A 99 106.93 -58.73 REMARK 500 CYS A 119 -70.53 -83.03 REMARK 500 ARG A 149 -8.03 84.25 REMARK 500 ALA A 172 108.40 -51.84 REMARK 500 MET A 194 -53.36 -164.76 REMARK 500 ASN A 196 -102.52 73.01 REMARK 500 TRP A 197 -32.37 71.45 REMARK 500 MET A 198 -173.68 62.31 REMARK 500 PRO A 224 36.22 -78.38 REMARK 500 PRO A 350 169.77 -49.01 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE P38 A 501 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3BV3 RELATED DB: PDB REMARK 900 SAME PROTEIN IN COMPLEX WITH INHIBITOR P39 DBREF 3BV2 A 2 360 UNP Q16539 MK14_HUMAN 2 360 SEQADV 3BV2 MET A -5 UNP Q16539 EXPRESSION TAG SEQADV 3BV2 ALA A -4 UNP Q16539 EXPRESSION TAG SEQADV 3BV2 HIS A -3 UNP Q16539 EXPRESSION TAG SEQADV 3BV2 HIS A -2 UNP Q16539 EXPRESSION TAG SEQADV 3BV2 HIS A -1 UNP Q16539 EXPRESSION TAG SEQADV 3BV2 HIS A 0 UNP Q16539 EXPRESSION TAG SEQADV 3BV2 HIS A 1 UNP Q16539 EXPRESSION TAG SEQRES 1 A 366 MET ALA HIS HIS HIS HIS HIS SER GLN GLU ARG PRO THR SEQRES 2 A 366 PHE TYR ARG GLN GLU LEU ASN LYS THR ILE TRP GLU VAL SEQRES 3 A 366 PRO GLU ARG TYR GLN ASN LEU SER PRO VAL GLY SER GLY SEQRES 4 A 366 ALA TYR GLY SER VAL CYS ALA ALA PHE ASP THR LYS THR SEQRES 5 A 366 GLY LEU ARG VAL ALA VAL LYS LYS LEU SER ARG PRO PHE SEQRES 6 A 366 GLN SER ILE ILE HIS ALA LYS ARG THR TYR ARG GLU LEU SEQRES 7 A 366 ARG LEU LEU LYS HIS MET LYS HIS GLU ASN VAL ILE GLY SEQRES 8 A 366 LEU LEU ASP VAL PHE THR PRO ALA ARG SER LEU GLU GLU SEQRES 9 A 366 PHE ASN ASP VAL TYR LEU VAL THR HIS LEU MET GLY ALA SEQRES 10 A 366 ASP LEU ASN ASN ILE VAL LYS CYS GLN LYS LEU THR ASP SEQRES 11 A 366 ASP HIS VAL GLN PHE LEU ILE TYR GLN ILE LEU ARG GLY SEQRES 12 A 366 LEU LYS TYR ILE HIS SER ALA ASP ILE ILE HIS ARG ASP SEQRES 13 A 366 LEU LYS PRO SER ASN LEU ALA VAL ASN GLU ASP CYS GLU SEQRES 14 A 366 LEU LYS ILE LEU ASP PHE GLY LEU ALA ARG HIS THR ASP SEQRES 15 A 366 ASP GLU MET THR GLY TYR VAL ALA THR ARG TRP TYR ARG SEQRES 16 A 366 ALA PRO GLU ILE MET LEU ASN TRP MET HIS TYR ASN GLN SEQRES 17 A 366 THR VAL ASP ILE TRP SER VAL GLY CYS ILE MET ALA GLU SEQRES 18 A 366 LEU LEU THR GLY ARG THR LEU PHE PRO GLY THR ASP HIS SEQRES 19 A 366 ILE ASP GLN LEU LYS LEU ILE LEU ARG LEU VAL GLY THR SEQRES 20 A 366 PRO GLY ALA GLU LEU LEU LYS LYS ILE SER SER GLU SER SEQRES 21 A 366 ALA ARG ASN TYR ILE GLN SER LEU THR GLN MET PRO LYS SEQRES 22 A 366 MET ASN PHE ALA ASN VAL PHE ILE GLY ALA ASN PRO LEU SEQRES 23 A 366 ALA VAL ASP LEU LEU GLU LYS MET LEU VAL LEU ASP SER SEQRES 24 A 366 ASP LYS ARG ILE THR ALA ALA GLN ALA LEU ALA HIS ALA SEQRES 25 A 366 TYR PHE ALA GLN TYR HIS ASP PRO ASP ASP GLU PRO VAL SEQRES 26 A 366 ALA ASP PRO TYR ASP GLN SER PHE GLU SER ARG ASP LEU SEQRES 27 A 366 LEU ILE ASP GLU TRP LYS SER LEU THR TYR ASP GLU VAL SEQRES 28 A 366 ILE SER PHE VAL PRO PRO PRO LEU ASP GLN GLU GLU MET SEQRES 29 A 366 GLU SER HET P38 A 501 44 HETNAM P38 5-METHYL-4-[(2-METHYL-5-{[(2-MORPHOLIN-4-YLPYRIDIN-4- HETNAM 2 P38 YL)CARBONYL]AMINO}PHENYL)AMINO]-N-(1-PHENYLETHENYL) HETNAM 3 P38 PYRROLO[2,1-F][1,2,4]TRIAZINE-6-CARBOXAMIDE FORMUL 2 P38 C33 H32 N8 O3 FORMUL 3 HOH *97(H2 O) HELIX 1 1 SER A 61 MET A 78 1 18 HELIX 2 2 SER A 95 PHE A 99 5 5 HELIX 3 3 LEU A 113 GLN A 120 1 8 HELIX 4 4 THR A 123 SER A 143 1 21 HELIX 5 5 LYS A 152 SER A 154 5 3 HELIX 6 6 ALA A 184 ARG A 189 5 6 HELIX 7 7 THR A 203 THR A 218 1 16 HELIX 8 8 ASP A 227 GLY A 240 1 14 HELIX 9 9 GLY A 243 LYS A 248 1 6 HELIX 10 10 SER A 252 SER A 261 1 10 HELIX 11 11 ASN A 269 PHE A 274 1 6 HELIX 12 12 ASN A 278 LEU A 289 1 12 HELIX 13 13 THR A 298 ALA A 304 1 7 HELIX 14 14 HIS A 305 ALA A 309 5 5 HELIX 15 15 GLN A 325 ARG A 330 5 6 HELIX 16 16 LEU A 333 SER A 347 1 15 SHEET 1 A 2 PHE A 8 TYR A 9 0 SHEET 2 A 2 VAL A 20 PRO A 21 -1 O VAL A 20 N TYR A 9 SHEET 1 B 2 GLU A 12 LEU A 13 0 SHEET 2 B 2 THR A 16 ILE A 17 -1 N THR A 16 O LEU A 13 SHEET 1 C 5 TYR A 24 GLY A 31 0 SHEET 2 C 5 VAL A 38 ASP A 43 -1 O VAL A 38 N GLY A 31 SHEET 3 C 5 ARG A 49 LYS A 54 -1 O VAL A 52 N CYS A 39 SHEET 4 C 5 TYR A 103 HIS A 107 -1 O LEU A 104 N LYS A 53 SHEET 5 C 5 ASP A 88 PHE A 90 -1 N ASP A 88 O VAL A 105 SHEET 1 D 3 ALA A 111 ASP A 112 0 SHEET 2 D 3 LEU A 156 VAL A 158 -1 O VAL A 158 N ALA A 111 SHEET 3 D 3 LEU A 164 ILE A 166 -1 O LYS A 165 N ALA A 157 SITE 1 AC1 22 ALA A 51 LYS A 53 GLU A 71 LEU A 75 SITE 2 AC1 22 ILE A 84 LEU A 104 THR A 106 HIS A 107 SITE 3 AC1 22 LEU A 108 MET A 109 GLY A 110 ALA A 111 SITE 4 AC1 22 ASP A 112 ILE A 141 HIS A 148 LEU A 167 SITE 5 AC1 22 ASP A 168 PHE A 169 LEU A 171 ARG A 173 SITE 6 AC1 22 HOH A 502 HOH A 547 CRYST1 64.879 74.175 77.848 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015413 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013482 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012846 0.00000 MASTER 269 0 1 16 12 0 6 6 0 0 0 29 END